Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. ALBANESE (Creteil, France), S. Dumas (Le Plessis Robinson, France), B. Ranchoux (Le Plessis Robinson, France), S. Shamdani (Creteil, France), S. Chantepie (Creteil, France), M. Huynh (Creteil, France), D. Montani (Le Kremlin Bicetre, France), B. Girerd (Le Kremlin Bicetre, France), P. Dorfmuller (Le Plessis Robinson, France), E. Fadel (Le Plessis Robinson, France), P. Dartevelle (Le Plessis Robinson, France), F. Perros (Le Plessis Robinson, France), M. Humbert (Le Kremlin Bicetre, France), D. Papy-Garcia (Creteil, France), S. Cohen-Kaminsky (Le Plessis Robinson, France). Fine structural modifications of heparan sulfate sulfation patterns in lung are associated with functional effects in Precapillary Pulmonary Hypertension. 3936

Member's Comments

No comment yet.

Related content which might interest you: Alterations in the expression of proteoglycans and glycosaminoglycans in pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006 Lung heparan and chondroitine sulfate imbalance and functional changes in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Diaphragm dysfunction in chronic obstructive pulmonary disease: a role for heparan sulphate? Source: Eur Respir J 2007; 30: 80-89 Year: 2007 Perlecan and heparan sulphate are abundant in fibroblast foci in Idiopathic Pulmonary Fibrosis. Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis Year: 2017 Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Hyaluronic acid, heparan sulfate and chondroitin sulfate are altered during exacerbations of COPD Source: International Congress 2017 – Infection and exacerbation science Year: 2017 The myofibroblast in pulmonary fibrosis displays distinct functional characteristics, depending on its source of origin Source: International Congress 2014 – ILDs 3 Year: 2014 Analysis of miRNA profile in circulating microparticles of patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease Source: Eur Respir J 2016; 48: 1215-1218 Year: 2016 Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis Source: International Congress 2017 – Rare diseases Year: 2017 Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Functional and molecular disparities between mesenchymal stem cells from various pulmonary disorders Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014 Differential expression of tenascin C splice variants in endobronchial epithelial-lining fluid in proximity of pulmonary nodules Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Predictors for significant changes in serum sulfated glycosaminoglycans at COPD exacerbations Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair Year: 2019 Functional characterization of BMPR2 gene in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 LATE-BREAKING ABSTRACT: The bromodomain-containing protein 4: the epigenetic origin of the oncogenic signature in pulmonary hypertension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Age-dependent systemic elastin degradation is enhanced in chronic obstructive pulmonary disease Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Adventitial remodeling of experimental pulmonary hypertension induces myofibroblast-produced collagen V in a Th17-pathways-related manner Source: International Congress 2016 – Pulmonary hypertension: novel insights Year: 2016 Pulmonary arterial lesions and interstitial remodeling patterns in histology differentiate EIF2AK4 mutation-carriers from non-carriers with pulmonary veno-occlusive disease Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Mutational and epigenetic analysis of the promoter region of BMPR2 gene in patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014